Gilead Sciences Posts 8% Revenue Growth in Q1 2026, Boosted by HIV and Oncology Launches
Event summary
- Gilead Sciences reported a 4% year-over-year revenue increase to $7.0 billion in Q1 2026, driven by 10% growth in HIV products and a 37% rise in Trodelvy sales.
- The company raised its full-year revenue guidance, citing strong performance and anticipated launches in oncology and inflammation.
- Gilead completed acquisitions of Arcellx, Ouro Medicines, and Tubulis, with implied equity values of $7.8 billion, $1.675 billion, and undisclosed, respectively.
- Diluted earnings per share increased to $1.61 from $1.04 in Q1 2025, primarily due to higher product sales and lower acquired IPR&D expenses.
- The company announced FDA acceptance of new drug applications for BIC/LEN and anito-cel, with PDUFA target action dates in August and December 2026.
The big picture
Gilead's Q1 2026 results reflect a strategic pivot towards oncology and inflammation through targeted acquisitions, complementing its strong HIV portfolio. The company's ability to navigate regulatory hurdles and integrate new assets will be key to maintaining its growth trajectory amid a competitive biopharmaceutical landscape. With up to four potential launches and five Phase 3 updates anticipated in 2026, Gilead is positioning itself for sustained growth in the near and long term.
What we're watching
- Pipeline Execution
- The success of Gilead's anticipated four potential launches and five Phase 3 updates in 2026 will be critical to sustaining growth.
- Integration Challenges
- The pace at which Gilead can integrate and leverage assets from Arcellx, Ouro Medicines, and Tubulis will impact its long-term strategy.
- Regulatory Approvals
- The outcome of FDA reviews for BIC/LEN and anito-cel will determine the timeline for new revenue streams in HIV and oncology.
Related topics